Tencent-backed (HKG:0700) InSilico Medicine (HKG:3696) entered into a multi-year research and development collaboration with Servier, an independent international pharmaceutical company, according to a Hong Kong bourse filing Monday.
Under the collaboration, Servier will use InSilico's AI-driven drug discovery platform to develop new therapies for cancer.
The collaboration is valued at up to $888 million, including up to $32 million in upfront and near-term research and development payments.
InSilico Medicine went public in Hong Kong the previous week.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments